PepGen PEPG
NASDAQ PEPG
$3.11 -0.07 (-2.20%)
As of: Sep 4, 2026 · 3:59 PM EDT

PepGen (PEPG) Accumulated Expenses (2021 - 2026)

PepGen (PEPG) posted Accumulated Expenses of $1.4 million for Q1 2026, down 69.33% sequentially from $4.7 million in Q4 2025, and down 90.22% YoY from $14.6 million in Q1 2025.

Analysis

PepGen (PEPG) Accumulated Expenses (2021 - 2026) Analysis & Trends

PepGen has reported Accumulated Expenses for 6 years, with the latest figure at $1.4 million in Q1 2026.

  • Quarterly Accumulated Expenses fell 90.22% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 90.22% YoY) and the FY2025 annual result came in at $4.7 million, up 28.92% from the prior year.
  • Accumulated Expenses retreated to $1.4 million in Q1 2026 per PEPG's latest filing, from $4.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $15.2 million in Q2 2022 and troughed at $635000.0 in Q1 2022.
  • A 5-year average of $5.7 million and a median of $3.1 million in 2025 frame the typical range for Accumulated Expenses.
  • The sharpest annual moves came in 2025 and 2026: Accumulated Expenses jumped 1211.94% in 2025, then plunged 90.22% in 2026.
  • Over 5 years, Accumulated Expenses stood at $2.4 million in 2022, then dropped by 2.95% to $2.4 million in 2023, then jumped by 52.74% to $3.6 million in 2024, then climbed by 28.92% to $4.7 million in 2025, then plunged by 69.33% to $1.4 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods registered $1.4 million, $4.7 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 PepGen 217.99 Mn 217.99 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.68 Mn
Mar 31, 2026 5.13 Mn
Dec 31, 2025 8.64 Mn
Sep 30, 2025 8.71 Mn
Jun 30, 2025 12.36 Mn
Mar 31, 2025 14.62 Mn
Dec 31, 2024 11.85 Mn
Sep 30, 2024 7.81 Mn
Jun 30, 2024 11.32 Mn
Mar 31, 2024 6.75 Mn
Dec 31, 2023 13.52 Mn
Sep 30, 2023 13.98 Mn
Jun 30, 2023 11.63 Mn
Mar 31, 2023 12.90 Mn
Dec 31, 2022 11.91 Mn
Sep 30, 2022 10.90 Mn
Jun 30, 2022 15.19 Mn
Mar 31, 2022 14.23 Mn
Dec 31, 2021 7.08 Mn